Hunan Cancer Hospital
🇨🇳China
Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06022770
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06011330
- Locations
- 🇨🇳
Hunan Cancer Hospital, ChangSha, Hunan, China
A Real-world Study of Inetetamab for First-line Treatment of MBC
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05980208
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Completed
- Conditions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT05942768
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05940532
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05869097
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05842525
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05633914
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05561686
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05535413
- Locations
- 🇨🇳
Quchang Ouyang, Changsha, China
© Copyright 2024. All Rights Reserved by MedPath